Response-guided Triple-therapy Using Boceprevir in Combination With PEGIFN/RBV in HIV/HCV-coinfected Patients
Phase of Trial: Phase IV
Latest Information Update: 20 Mar 2017
Price : $35 *
At a glance
- Drugs Boceprevir (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C; HIV infections
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 15 Dec 2016 Status changed from recruiting to completed.
- 14 Sep 2013 New source identified and integrated (European Clinical Trials Database, 992366).